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Abstract: The virion proteins of Kaposi sarcoma-associated herpesvirus (KSHV) were initially
characterized in 2005 in two separate studies that combined the detection of 24 viral proteins
and a few cellular components via LC-MS/MS or MALDI-TOF. Despite considerable advances
in the sensitivity and specificity of mass spectrometry instrumentation in recent years, leading to
significantly higher yields in detections, the KSHV virion proteome has not been revisited. In this study,
we have re-examined the protein composition of purified KSHV virions via ultra-high resolution Qq
time-of-flight mass spectrometry (UHR-QqTOF). Our results confirm the detection of all previously
reported virion proteins, in addition to 17 other viral proteins, some of which have been characterized
as virion-associated using other methods, and 10 novel proteins identified as virion-associated for the
first time in this study. These results add KSHV ORF9, ORF23, ORF35, ORF48, ORF58, ORF72/vCyclin,
K3, K9/vIRF1, K10/vIRF4, and K10.5/vIRF3 to the list of KSHV proteins that can be incorporated into
virions. The addition of these proteins to the KSHV virion proteome provides novel and important
insight into early events in KSHV infection mediated by virion-associated proteins. Data are available
via ProteomeXchange with identifier PXD022626.
Keywords: KSHV virion proteome; viral proteomics; bottom-up shotgun proteomics; UHR-QqTOF
1. Introduction
Kaposi’s sarcoma herpes virus (KSHV) was first discovered about twenty-five years ago through
the use of representational difference analysis by Chang et al. [1], and about a year later, Moore et al. [2]
looked into similarities of this novel virus with other known gammaherpesviruses and were able to
identify it as the most similar with herpesvirus saimiri (HVS) through gene alignment and amino
acid sequencing alignments on Open Reading Frames (ORFs) suitable for phylogenetic analysis;
however, they noted that the divergence between the viruses is ancient. They, furthermore, classified
this virus as the first human gamma-2 herpesvirus. To this day, KSHV is the only viral agent of the
rhadinoviral subfamily capable of infecting human B cells [1]. In the context of immunosuppression,
KSHV infection causes Kaposi’s sarcoma, an endothelial cell neoplasm, the B cell lymphoproliferative
disorders primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD), as well as a
recently discovered KSHV inflammatory cytokine syndrome disease (KICS) [3].
As with all herpesviruses, KSHV undergoes either latent or lytic infection programs. New virions
are produced during the lytic phase, and latency is used for long-term maintenance of viral genomes
as extra-chromosomal episomes [4]. Although different environmental and physiological signals,
such as viral-coinfections [5], hypoxia [6], oxidative stress [7]; cellular factors and cellular signaling [8],
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such as histone deacetylases [9], and even dietary supplements [10] can cause KSHV lytic reactivation,
latency is thought to be the predominant mode of KSHV infection in human hosts. However, there is
convincing evidence that lytic replication plays a significant role in KSHV-associated pathology [11].
Despite the substantial body of work on KSHV, early infection events in disease-relevant cell types
and the role of individual virion-associated tegument factors in the establishment of infection remain
poorly studied [12].
The tegument layer is a dense proteinaceous layer sandwiched between the nucleocapsid and the
virion envelope that can critically affect the host’s cellular and viral biology immediately following
viral entry [13]. These proteins make up a large proportion of the virion’s overall protein composition,
and they serve as prepackaged factors capable of influencing the host cell physiology immediately upon
the fusion of the viral envelope with the host cell membrane. Early infection functions of tegument
proteins include cell cycle modulation [14], transcriptional activation of viral genes [15], inhibition of
host gene expression activation [16], translocation of the virion capsid to the nucleus [17], and evasion
of the innate immune response. Thus, identification and functional analysis of the virion proteins of
KSHV is a critical step in understanding the early stages of KSHV infection.
In 2005, two research groups independently characterized the virion proteins of KSHV derived
from lytic induction of latently infected BCBL-1 PEL cells. These studies both utilized a bottom-up
proteomics approach to characterize virion-associated proteins by extracting individual protein bands
visible on SDS-PAGE gels of purified virions, using either MALDI-TOF [18] or LC, MS/MS [19] to
identify the individual proteins after tryptic digestion. These studies together identified 24 viral and
a few cellular proteins as virion associated. Additional proteins have since been detected in KSHV
virions via other methods [20–27]; however, despite significant advances in proteomics methods and
instrumentation in recent years, the KSHV virion proteome has not been revisited.
Advances in proteomics technology have given rise to de novo sequencing in shotgun
proteomics [28], which combines high-resolution spectrum data from modern mass spectrometry
instruments with automated de novo peptide sequencing algorithms. These technological advances,
combined with enhancements in sample preparation, have revolutionized proteomics in the last
ten years.
In this study, we have taken advantage of advanced instrumentation and analysis methods;
to reanalyze the KSHV virion proteome using a bottom-up shotgun method [29], combined with de
novo sequencing on highly purified KSHV virions produced from the iSLK the epithelial cell line as
well as dual digestion with trypsin/lys-c and chymotrypsin. Our method’s improved sensitivity has
allowed us to validate all of the 24 previously reported virion-associated proteins and add seventeen
other proteins to the KSHV virion proteome. Seven of our novel proteomic hits have been identified
as virion-associated by non-proteomic methods, and we report ten proteins in our analysis that have
never previously been identified as virion-associated.
2. Materials and Methods
2.1. Purification of Cell-Free KSHV Virions
Latently infected iSLK producer cells stably infected with BAC16 recombinant KSHV WT
were grown to 70–75% confluency in DMEM (Caisson Labs, Smithfield, UT, United States
Catalog#: DML10—500 ML) supplemented with 10% cosmic calf serum (Sigma-Aldrich, St. Louis,
MO, United States Catalog#: C8056—500 ML), 250 µg/mL geneticin (Goldbio, St. Louis, MO,
United States Catalog#: G-418-1), 1 µM puromycin (Bio Basic, Markham, ON, Canada Catalog#: PJ593),
and 1.2 mg/mL hygromycin B (A.G. Scientific, San Diego, CA, United States Catalog#: H-1012-PBS).
Then induced for 72 h with 3 mM sodium butyrate (Sigma-Aldrich, St. Louis, MO, United States
Catalog#: B5887-1G) and 2 µM doxycycline (Tocris, Minneapolis, MN, United States Catalog#:
4090—50 mg). Culture supernatants were clarified by centrifugation at 500 g for 12 min and passed
through a 0.45 uM filter placed on ice. The virus was then pelleted out of clarified supernatants over a 50%
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Opti-prep (Iodixanol) [30] cushion prepared in TNE buffer at pH 7.40 by ultracentrifugation at 41,000 g
for 120 min using an SW28 rotor. Immediately after (adapting a previously reported purification method
used for mass spectrometry of virions), the concentrated virus particles were centrifuged through
a 10–50% Iodixanol density step gradient prepared in TNE buffer [31] at 45,000 g for 2 h. The virus band
at the gradient junctions of 22–24% was collected and kept at −80 ◦C for further processing. Iodixanol
fractions were also collected and the viral DNA was extracted from them using the Zymo Quick
DNA/RNA Viral kit (Zymo Research, Irvine, CA, United States Catalog#: D7020). Endpoint RFU qPCR
assay was then performed on DNA fractions using probes and primers against LANA (LANA forward
(5′-AATGGGAGCCACCGGTAAAG-3′), LANA reverse (5′- CGCCCTTAACGAGAGGAAGT-3′),
LANA probe (5′ [6FAM]-ACACAAATGCTGGCAGCCCG-[BHQ1]3′)) using TaqProbe 5× qPCR
MasterMix-Multiplex (ABM MasterMix-5PM), 5% DMSO, primers at 900 nM and probes at 250 nM on
BioRad(Hercules, CA, United States ) CFX qPCR machine in 40 cycles.
2.2. Trypsin and Detergent Treatment of Purified Virions
The purified virion sample was then divided into two fractions. One fraction was treated with
0.25% trypsin- 2.21 mM EDTA for 60 min at 37 ◦C, while shaking at 300 rpm, to cleave and strip
external envelope proteins and non-viral proteins and debris from virion preparations followed by
virion lysis. This fraction is herein referred to as VTT fraction. The second fraction was kept untreated
and is herein referred to as VT fraction. Both fractions were then treated with Pierce protease inhibitor
(Thermo Scientific, Waltham, MA, United States Catalog#: A32963). Proteins were extracted and lipids
removed using ReadyPrep 2D-Cleanup Kit (BioRad, Hercules, CA, United States Catalog#: 1632130).
Protein concentration was then quantified using a Qubit 3.0 fluorometer (Invitrogen, Waltham, MA,
United States). The sample concentration was adjusted to a minimum of 0.5 mg/mL and pH as adjusted
to (pH 7.5). The purified proteome samples were reduced and alkylated, using Thermofisher EasyPep™
Mini MS Sample Prep Kit (Thermo Fisher Scientific, Waltham, MA, United States Catalog#: A40006).
The samples were then either tryptic digested for 6–8 h at 37 ◦C in Tris-HCl buffer with final
protease to a protein ratio of 1:100 w/w of Pierce Trypsin/Lys-C to protease mix (Thermo Scientific,
Waltham, MA, United States Catalog#:1863467) or digested with Pierce Chymotrypsin Protease
(TLCK-treated) (Thermo Fisher Scientific, Waltham, MA, United States Catalog#: 90056) with final
protease to protein ratio of 1:100 w/w, for 12–14 h at 37 ◦C in 1 mM HCl, while shaking at 300 rpm.
The digestion was stopped using the digestion stop reagent of the EasyPep™Mini MS Sample Prep
Kit, and the samples were further cleaned and filtered following the kit’s protocol. The samples were
then extracted in 0.1% formic acid in diH2O and kept at −80◦C until analysis.
2.3. Mass Spectrometry Analysis
The samples were thawed on ice, and 50 uL of the peptide digest fraction was then
injected onto a reverse-phase C18 Acclaim RSLC 120 column (Thermo Scientific, Waltham, MA,
United States Catalog#:074812) at 2.2 um and 120◦A 2.1 × 250 mm connected to an ultra-high
performance liquid chromatography (UHPLC) coupled to an electrospray ionization source of an ion
trap mass spectrometer (Bruker Impact II UHR-QqTOF LC/MS). The sample was separated within
75 min with 0.2 mL/minute flow rate. A gradient method started at 99% buffer A (0.1% Formic acid in
water) and 1% buffer B (0.1% Formic acid in Acetonitrile) and held at 1% B for 5 min. The gradient was
changed linearly to 55% B in 60 min, and then changed to 90% B in 10 min. Finally, it was held for
5 min to equilibrate back to 1% B initial condition. The column oven set at 37 ◦C.
QTOF parameters for electrospray capillary at 4.5 V dry gas was set to 8 L/min. Dry temperature
was set to 200 ◦C. Nebulizer was set to 1.8 Bar. Target mass range was set from 300 to 1600 m/z.
Collision cell energy was set to 8 eV. Transfer time was set to 90 µs, and pre-pulse storage was set to
10 µs. Spectra rate was set to 2 Hz with Auto MS/MS Spectra rate upper limit of 30 and lower limit
of 4 and only the most intense precursor ions were selected for fragmentation and cycle time of 3 s.
Dynamic exclusion duration was 0.3 min and exclude singly charged m/z. Precursor ions isolation
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was m/z dependent window of 2–5. The collision energy was adjusted, as a function of m/z value,
between 23–65 eV, the system was calibrated using 10 mM sodium formate solution, and the accepted
range was set to 250–1600 m/z.
Utilizing PEAKS DB, PEAKS PTM, and SPIDER search tools from PEAKS Studio
(software version10)(78), the mzxml files were analyzed against a sequence database with the
HHV8 protein database’s customized library pulled from Uniprot (Swiss-prot) (https://www.
uniprot.org/uniprot/?query=reviewed:yes%20taxonomy:37296#) downloaded on 07/01/2020 containing
86 sequences. Trypsin (for trypsin digested samples) and chymotrypsin (for samples digested
with chymotrypsin) were selected with a maximum of three missed cleavages permitted; the search
parameters were set to fixed modification of Carbamidomethyl and variable modification of methionine
oxidation. Additional criteria used in the search were peptide mass tolerance of ±20.0 ppm,
and fragment mass tolerance of ±0.05 Da followed with the peptide score p-value of less than
0.00316. Using the Spider search feature, a special feature in PEAKS software, a single amino acid
mutation and up to three additional modifications per peptide were automatically detected with
PTM_Ascore of 20 and mutation ion intensity of 5%. All of reported peptides (Tables S1–S6) have
a score (−10lgP) greater than 25 and corresponding to a statistically significant (p < 0.00316) confident
identification; moreover, from our positive matches, only proteins identified with more than at least
3 peptide sequences with a mass tolerance of <0.05 Da were reported. An exception was made for
the two previously reported ORF53 and ORF28, which are very small in size and contain a limited
number of trypsin cleavage sites when using trypsin. However, using chymotrypsin, we were able
to report more hits for both proteins. Additionally, we queried a common contaminants database to
ensure the overall quality of the samples. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE [32] partner repository with the dataset identifier
PXD022626 and 10.6019/PXD022626 [33,34].
2.4. Antibodies and Western Blotting
Purified virion proteome equivalent to 1:50 of the final yield was mixed 1:1 with 5× Laemmeli
buffer (0.5M Tris-HCl PH6.8, Glycerin, S.D.S., 0.25%Bromophenol blue, B-mercaptoethanol) boiled
for 10 min at 95 ◦C and then run on Mini-Protean T.G.X. Stain Free 4–15% Bis-Tris PAGE gels
(BioRad, Hercules, CA, United States, Catalog#:4561081), then transferred to chemiluminescence
Polyvinylidene difluoride(PVDF) membranes (Amersham, Buckinghamshire, United British Kingdom,
Catalog#:88585). The membranes were dry-blocked overnight and rehydrated with 2% dried milk
in T.B.S. buffer and then incubated with diluted primary antibodies against ORF8 (gB) (Invitrogen,
Waltham, MA, United States, Catalog#:PA5-19852) or B-actin (Cell Signaling technology, Danvers,
MA, United States, Catalog#8H10D10) as the housekeeping control for four h at room temperature
or 4 ◦C overnight. Anti-rabbit or anti-mouse immunoglobulin G antibody conjugated to horseradish
peroxidase (Invitrogen, Waltham, MA, United States) was used as the secondary antibody. The enhanced
chemiluminescence system (BioRad, Hercules, CA, United States, Catalog#: 1705060S) was used to
detect antibody–antigen complexes using the BioRad Universal Hood II gel imager.
For the iodixanol fractions each fraction was collected then mixed 1:1 with 5x Laemmeli buffer
(0.5M Tris-HCl PH6.8, Glycerin, S.D.S., 0.25% Bromophenol blue, B-mercaptoethanol) boiled for
10 min at 95 ◦C and then run on two similar Mini-Protean T.G.X. Stain Free 4–15% Bis-Tris PAGE
gels (BioRad, Hercules, CA, United States, Catalog#:4561081), post run one of the gels were stained
with Coomassie blue (0.05% Coomassie brilliant blue, 50% methanol, 10% acetic acid) for 1 h,
and destained (50% methanol, 10% acetic acid) for 3 h. The second gel was then transferred
to chemiluminescence PVDF membranes (Amersham, Buckinghamshire, United British Kingdom,
Catalog#:88585). The membrane was dry-blocked overnight and rehydrated with 2% dried milk
in T.B.S. buffer and then incubated with diluted primary antibody against ORF8 (gB) (Invitrogen,
Waltham, MA, United States, Catalog#:PA5-19852) four hours at room temperature or 4 ◦C overnight.
Anti-rabbit G antibody conjugated to horseradish peroxidase (Invitrogen, Waltham, MA, United States)
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was used as the secondary antibody. The enhanced chemiluminescence system (BioRad, Hercules, CA,
United States, Catalog#: 1705060S) was used to detect antibody–antigen complexes using C-DiGit Blot
Scanner (Li Cor Biosciences, Lincoln, NE, United States).
3. Results
3.1. Purification of Cell Free KSHV Virions and Virion Protein Fractions
One of the significant limitations of the original KSHV proteomics studies was the production
of high-yield purified virions from BCBL1 cells sufficient to obtain a high protein concentration for
analysis. In this study, we employed the more recent and highly productive iSLK producer cell line to
produce KSHV virions from the recombinant BAC16 KSHV genome for our studies [35]. iSLK cells
were induced at confluency with doxycycline and sodium butyrate, and at 72 h post-induction, virions
were purified from 2 L of filtered culture supernatants for further processing. Adopting a method
previously reported for KSHV virion purification for mass spectrometry [31], the supernatant was then
ultracentrifuged over a 50% Iodixanol (Opti prep) [30] cushion, the cell free virions in 50% iodixanol
were collected and further purified by ultracentrifugation on a 10–50% Opti-Prep in TNE buffer density
step gradient to ensure further cleanup of the sample. Virus was quantitated by real-time qPCR
using LANA as a genomic target. A genome peak was obtained at the 22–24% Opti-Prep interface
(Figure 1a). Fractions were then used in Coomassie blue staining and Western blotting against the
ORF8(gB) antibody to determine the purity and concentration of virions in these fractions (similar
to methodology used in Bechtel et al. [18]), respectively, (Figure 1b), and only the fractions around
22–24% iodixanol were collected and labeled as V fraction and kept at −80 ◦C for further processing.
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Figure 1. (a) Endpoint RF q using LANA genome on Iodixanol fractions. (b) Top Coomassie
blue staining of the Iodixanol gradient fractions. (b) Bottom Western blot using gB/ORF8 antibody on
different iodixanol gradient fractions to ensure the quality of the virion purification, based on the data,
only fractions of 22–24% Iodixanol containing virions was used for further processing. This fraction
was labeled as fraction V. (c) Western blot for gB/ORF8 on proteins from trypsin digested (VTT) and
purified (VT) fractions as well as virions.
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The V fraction was then divided into two equal fractions, one where the proteins were extracted
and then digested with either trypsin/LysC or chymotrypsin, referred to as VT fraction. The second
was exposed to 0.25% trypsin- 2.21 mM EDTA for 60 min at 37 ◦C, while shaking at 300 rpm to strip the
envelope layer and possible cellular debris before protein extraction and purification using labeled as
the VTT fraction. The quality and purity of these fractions and the efficacy of external trypsin treatment
was validated by Western blotting for ORF8/gB and B-actin (Figure 1c).
3.2. Mass Spectrometry Quality Control
As the VT fraction contains both glycoproteins as well as envelope contained proteins, it was used
for the initial mass spectrometry analysis of probing for previously reported virion proteins. PEAKS
Studio software (Version 10) [36] was used for all of the data analysis presented herein. Using the
database search approach, the raw datafiles were analyzed against a customized library of HHV8
protein database pulled from Uniprot (Swissprot) ((https://www.uniprot.org/uniprot/?query=reviewed:
yes%20taxonomy:37296#) downloaded on 07/01/2020 containing 86 sequences). Trypsin (for trypsin
digested samples) and chymotrypsin (for samples digested with chymotrypsin) were selected with
a maximum of three missed cleavages permitted; the search parameters were set to fixed modification
of carbamidomethyl and variable modification of methionine oxidation. Additional criteria used in the
search were peptide mass tolerance of ±20.0 ppm, and fragment mass tolerance of ±0.05 Da followed
with the peptide score p-value of less than 0.00316. Using the Spider search feature, a special feature in
PEAKS software, a single amino acid mutation and up to three additional modifications per peptide
were automatically detected with PTM, a score of above 20 and mutation ion intensity of 5%. All of the
reported peptides (included in Tables S1–S6) have a score (−10logP) greater than 25, corresponding to
a statistically significant (p < 0.00316) confident identification. Moreover, from our positive matches,
only proteins identified with more than at least three peptide sequences with a peptide mass tolerance
of <20 ppm detected in triplicate runs were reported. It should be noted that similar to Zhu et al. [19],
for the previously reported ORFs 28 and 53, due to the smaller size of the proteins, and limited trypsin
cleavage cites, an exception was made were two and one peptide hits with trypsin were also accepted;
however, using chymotrypsin, we detected three and two unique peptide hits, respectively.
An example of the quality control statistics and our applied methodology is shown in Figure 2.
At an false discovery rate (FDR) = 1.0% (Figure 2a), 203 peptide matches were accepted following the
other criteria including the –log p, which is set at 25 (Figure 2b) corresponding to the p-value of less
than 0.01, demonstrating our sacrifice in reduction in the decoy hits in exchange for increase in true
peptide match score. This decrease of p-value indicating the ppm peptide error is demonstrated and
the blue dots are the high-quality hits (Figure 2c). Although the PEAKS DB database search feature
was mainly used for our analysis, the PEAKS de novo sequencing feature was also used and Table S8
shows a few examples of some of our sequences with the ALC% cut-off of 75%. Figure 2d,e respectively
show the distribution of our detected peptide features as well as the increasing trend in the accuracy of
the de novo peptide match sequencing with a tight error tolerance.
3.3. KSHV Virion Protein Identification
Using the MS methodology mentioned above, we detected all 25 previously reported virion
proteins that were identified by Bechtel et al. [18] and Zhu et al. [19] (Table 1, Tables S1 and S4).
We detected ORFs 18, 32, 38, 42, 43, 56, and K2, which were not identified as virion-associated in the
first proteomic studies but have since been identified as virion proteins by other methods [20–27]
(Table 2, Tables S2 and S5). Finally, we detected 10 KSHV proteins that have not been previously
reported as virion associated. These novel virion proteins are ORFs 9, 23, 35, 48, 58, 72, K3, K9, K10,
K10.5 (Table 3, Tables S3 and S6). Figure 3 shows an example of the protein coverage in our study
(Figure 3) where a detected peptide sequence hit of ORF52 (DRPLTATEK) with –10lgp of 44.48 with
an m/z of 515.7792, z = 2 using Collision-Induced Dissociation (CID) activation mode on qTOF detected
Via PEAKS Studio software.
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Impact II UHR-QqTOF 125 LC/MS system identified with PEAKS Studio software.
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Table 1. Proteins identified in the VT fraction in our study that were previously reported by
mass spectrometry.
Gene Protein aa Size Previous Reportby MS
Number of Unique
Peptide Hits via
Trypsin Digest
Number of Unique
Peptide Hits via
Chymotrypsin Digest
ORF6 Major DNA-bindingprotein (MBP) 1133 Zhu et al. [19] 7 6
ORF7 Tripartite terminasesubunit 1 (TRM1) 695 Zhu et al. [19] 6 3
ORF8 Envelope glycoproteinB (gB) 845
Zhu et al. [19],
Bechtel et al. [18] 10 20
ORF11 ORF11 407 Zhu et al. [19] 9 5
ORF17 Capsid Scaffoldingprotein 534 Zhu et al. [19] 3 3
ORF21 Thymidine kinase 580 Zhu et al. [19],Bechtel et al. [18] 8 3
ORF22 Envelope glycoproteinH (gH) 730
Zhu et al. [19],
Bechtel et al. [18] 7 5
ORF24 ORF24 752 Bechtel et al. [18] 4 7
ORF25 Major capsid protein(MCP) 1376
Zhu et al. [19],
Bechtel et al. [18] 5 6
ORF26 Triplex capsid protein2 (TRX-2) 305
Zhu et al. [19],
Bechtel et al. [18] 5 3
ORF27 ORF27 290 Zhu et al. [19] 6 4
ORF28 ORF28 102 Zhu et al. [19] 2 3
ORF33
Cytoplasmic
envelopment protein 2
(CEP-2)
334 Zhu et al. [19],Bechtel et al. [18] 7 7
ORF39 Envelope glycoproteinM (gM) 400 Zhu et al. [19] 6 3
ORF45 ORF45 407 Zhu et al. [19] 5 4
ORF47 Envelope glycoproteinL (gL) 528 Zhu et al. [19] 5 3
ORF52 ORF52 131 Zhu et al. [19] 9 5
ORF53 Envelope glycoproteinN (gN) 110 Zhu et al. [19] 1 2
ORF62 Triplex capsid protein1 (TRX-1) 331
Zhu et al. [19],
Bechtel et al. [18] 4 3
ORF63 Inner tegument protein 927 Zhu et al. [19],Bechtel et al. [18] 7 5
ORF64 Large tegumentprotein deneddylase 2635 Zhu et al. [19] 6 12
ORF65
Small
capsomere-interacting
protein (SCP)
170 Zhu et al. [19] 4 3
ORF68 Packaging proteinUL32 homolog 545 Zhu et al. [19] 3 4
ORF75 ORF75 1296 Zhu et al. [19],Bechtel et al. [18] 8 6
ORF K8.1 gp35/37 228 Zhu et al. [19] 4 4
Proteins identified in VT fraction of our study that were previously reported by mass spectrometry. All peptides
have a score (−10lgP) greater than 25 and correspond to a statistical significance of p < 0.00316; moreover, from our
positive matches, only proteins identified with more than at least 3 peptide sequences with a mass tolerance of
<0.05 Da were reported.
For some of the previously reported hits like ORF6 and ORF7, we were able to detect more unique
peptide fragments than were reported initially; however, for some other proteins such as ORF25,
the number of peptide hits we found was less than what was previously reported; Bechtel et al. [18]
explain that one reason for having so many peptides for ORF25 in their study could be that virions
were damaged during the purification and processing of their sample. Our reduced detection of
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ORF25 peptides could indicate that our altered sample preparation approach resulted in less damage
to virions prior to protein extraction.
Table 2. Proteins identified by mass spectrometry in our study that were previously reported by
other methods.
Gene Protein aa Size Previous Report by MS
Unique Peptide
Hits via Trypsin
Digest
Unique Peptide Hits
via Chymotrypsin
Digest
ORF18 Protein UL79homolog 257 Gong et al. [22] 4 4
ORF32
Capsid vertex
component 1
(CVC-1)
454 Dai et al. [20] 7 4
ORF38
Cytoplasmic
envelopment
protein 3 (CEP-3)
61 Wu et al. [21] 4 3
ORF42
Cytoplasmic
envelopment
protein 1 (CEP-1)
278 Butnaru et al. [23] 3 3
ORF43 Portal Protein 605 Dünn-Kittenplon et al. [24] 6 5
ORF48 ORF48 402 Sander et al. [25] 6 3
ORF56 DNA primase 843 Majerciak. [26] 6 4
ORF K2 Viral Interleukin 6Homolog 204 Katano, H. et al. [37] 12 7
Proteins identified in VTT fraction of our study that were previously reported by non-mass spectrometry methods.
All peptides have a score (−10lgP) greater than 25 and correspond to a statistical significance of p < 0.00316; moreover,
from our positive matches, only proteins identified with more than at least 2 peptide sequences with a mass tolerance
of <0.05 Da were reported.
Table 3. Virion-associated proteins identified that have not previously been reported by any method.
Gene Protein aa Size
Unique Peptide
Hits via Trypsin
Digest
−10lgP
(Trypsin)
Unique Peptide Hits
via Chymotrypsin
Digest
−10lgP
(Chymotrypsin)
ORF9 DPOL 1012 6 45.15 4 34.08
ORF23 ORF23 404 6 26.45 4 32.21
ORF35 ORF35 150 4 26.23 3 37.48
ORF58 ORF58 357 5 42.45 4 41.66
ORF72 viral cyclinhomolog 257 4 42.46 4 45.19
ORF K3
E3
ubiquitin-protein
ligase MIR1
333 5 35.01 3 32.7
vIRF-1 Viral IRF-likeprotein 1 449 5 39.12 4 26.26
vIRF-3 Viral IRF-likeprotein 3 566 7 27.51 3 26.50
vIRF-4 Viral IRF-likeprotein 4 911 11 37.95 5 30.02
ORF44
DNA
Replication
helicase
788 0 N/A 5 35.06
Novel proteins identified in VTT fraction. All peptides have a score (−10lgP) greater than 25 and correspond to
a statistical significance of p < 0.00316; moreover, from our positive matches, only proteins identified with more than
at least 2 peptide sequences with a mass tolerance of <0.05 Da were reported.
Additionally, we detected ORF44 peptides only with chymotrypsin digestion and not with
trypsin digestion, the peptide hits for this protein also followed our tight criteria of peptide mass
tolerance of 20 ppm and fragment mass tolerance of 0.01; in addition to that, they all have −10lgP > 25.
The identified peptides are included in Table S7.
It is important to note that we analyzed our dataset using a database containing only KSHV
protein sequences, so our analysis does not include any host proteins associated with the virion.
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Next, we wanted to confirm that our novel hits (Table 3) were actually encapsulated within the
virions and not due to debris that might have been coincidentally co-purified with the virion fraction.
To accomplish this, we pre-treated intact, purified virions with 0.25% trypsin-EDTA to eliminate any
proteins not being protected by the virion envelope before performing protein extraction and MS
analysis (VTT protein fraction). We used a Western blot for gB to validate the trypsin pre-treatment’s
efficacy in stripping the envelope layer (Figure 1c). Both original virion proteomic studies [18,19]
identified beta-actin as a cellular protein incorporated into KSHV virions, so we utilized this marker as
a loading control for this analysis. As expected, MS analysis of the digested pre-treated (VTT) protein
fractions included all of the protein hits shown in Tables 1–3 except for 10 proteins, including the eight
known glycoproteins ORFs 8, 22, 28, 39, 47, 53, 68, and K8.1, as well as ORF27 and one of our novel
detected proteins, ORF58. Thus, we can conclude confidently that nine of our novel virion proteins,
ORFs 9, 23, 35, 48, 72, K3, K9, K10, K10.5, are contained within the virion envelope and are not present
in the sample due to contamination of the virion preparation with free proteins that are not indeed
virion encapsulated. These results also support the prevailing hypothesis that ORFs 27 and 58 are
glycoproteins [38–40].
Moreover, these data reconfirm Zhu et al.’s [19] speculation that ORF28 is an envelope glycoprotein,
based on only its similarity in homology to EBV BDLF3 protein. Of the proteins mentioned in Table 2,
that have been introduced as tegument proteins of KSHV, ORF18 was reported by Gong et al. [22] to
be essential for de novo lytic activity and viral reactivation, which is in line with our observation of
this protein within the newly formed virions. Dai et al. [20] in 2014 reported ORF32 as a tegument
assembly mediator. ORF42 has been reported to be an essential post-translational regulator, and the
loss of it would result in the formation of fewer virion particles. ORF43 has been shown to function
as a gate for the packaging of viral DNA into procapsids and a further injection of it to the host
nucleus [25]. ORF56 plays a vital role in DNA replication and viral DNA synthesis and is reported to
be a primary lytic gene. Interestingly, its protein expression levels have been reported to be dependent
on ORF57 [26,41,42]. In our analysis, we also observed post-translational modifications including, but
not limited to, oxidation, carbamidomethylation, deamidation, and acetylation. These modifications,
where present, are indicated in the peptide sequences reported in Tables S1–S6. An example of some
PTMs observed in the ORF52 protein are shown in Figure 4. It should be noted that, although our
analysis was able to detect some PTMs and they are reported in our data, sample preparation for
bottom-up proteomics often introduces modifications during sample preparation. Observation of
the true spectrum of PTMs in KSHV virion proteins would require further studies using specialized
methodologies that were not employed here.
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4. Discussion
Since the emergence of system-wide protein analysis three decades ago, a common approach
to proteomics has been the 2D separation of proteins followed by in-gel trypsinization of individual
bands before sequencing and identification [43]. Despite its ease of use and flexibility, this technique
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has some significant drawbacks, including incomplete digestion, loss of sample, failure to detect
low abundance proteins, and limited dynamic range for proteins. These limitations have resulted in
a recent shift towards in-solution, gel-free, or “shotgun” proteomics [44]. Moreover, the development
of ultra-high-pressure LC systems in conjunction with smaller inner diameter columns and particle
size and development of algorithms and software for de novo sequencing has enabled the detection of
thousands of proteins in single LC-MS runs [28,45]. Our study has taken advantage of these advances
in proteomics technology to take a fresh look at the KSHV virion proteome.
The current study benefits majorly from a few advancements in KSHV research, some of which
were not accessible at the time of the original studies done by Bechtel et al. [18] and Zhu et al. [19].
In particular, the iSLK cell producer cell line has greatly improved KSHV virion yields compared to
previous systems isolating WT KSHV from PEL cell lines [35,46]. We believe this increased virion
yield, combined with modern instrumentation and analysis software, contributed substantially to the
increased sensitivity of our analysis.
EBV systems have shown that gamma-herpesvirus virions can have altered protein composition
based upon the producer cell type [47]. However, differences in KSHV virion protein composition
from different cell types have not been examined. Given that both original mass spectrometry studies
analyzed KSHV virions from PEL cell lines, we cannot determine whether our novel proteins are
a result of the increased sensitivity of our methods or the fact that these proteins are only incorporated
into virions when they are produced in iSLK or possibly generally from cells of epithelial origin.
Since the iSLK system has become increasingly prevalent in the field for the production of KSHV,
these results provide critical insight into the protein composition of the iSLK-derived virions, which are
commonly used for both in vitro and in vivo experimental studies of KSHV virology.
In addition to validating all of the previously reported proteins packaged within KSHV virions,
we report 10 novel virion-associated proteins. ORF58 encodes a homolog of EBV BMRF2 protein with
unknown functions [29], but together with ORF27, it has long been speculated to be a glycoprotein [38–40].
Our data that ORF58 is removed from the virion by pre-treatment of intact viral particles with trypsin
support the conclusion that this ORF58 is a glycoprotein. Similarly, although ORF27 was not novel
in our study, we showed that trypsin pre-treatment removed ORF27 from our virion proteome,
thus confirming Zhu et al. [19] primary classification of ORF27 as a glycoprotein.
Three additional novel virion proteins detected here are highly conserved among gamma
herpesviruses (ORF 23, 35, and 48). ORF23 binds to ORF34, and its specific function is still unknown [48].
However, a study in MHV68 has shown that its ortholog is not essential for in vitro and in vivo
infection [49]. ORF35 encodes a poorly characterized protein that is essential for viral reactivation [50].
A study of MHV68 ORF35 has shown that it is essential for efficient lytic replication and latency [51].
ORF48 is also poorly studied in KSHV, but a study on the homologous protein in MHV68 has
determined that this gamma-herpesvirus-conserved ORF is RTA-responsive and functions in both viral
lytic replication and latency during in vivo infections [52]. Future studies into the functions of these
proteins are needed to establish the implications of their presence in the virus particle.
ORF9 encodes the viral DNA polymerase [53] and interacts with K10/vIRF4 [25]. There is evidence
of ORF9 gene expression as early as 0–10 hours post-infection [41], implying that genome replication
is an important step early in the establishment of infection. ORF72 is the viral cyclin homolog,
which shares 54% sequence homology with the cellular Cyclin D2 [54–58] and binds to a number of
cellular cyclin-dependent kinases to promote proliferation of KSHV-infected cells [59–61] Packaging
ORF9 and ORF72 into the virus particle implies that early genome replication and manipulation of the
host cell cycle are critically important for the initial establishment of KSHV infection in a new host cell.
Our remaining novel virion proteins can broadly be classified as immunomodulatory and immune
evasion genes. K2 expresses the viral IL-6 homolog [62], which has significant immunomodulatory
effects during KSHV infection and KSHV-associated disease [63]. Although vIL-6 is known to
signal intracellularly in the endoplasmic reticulum to manipulate host cell processes in an autocrine
manner [64,65], we are unsure of the specific implications of the protein being contained in the
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virus particle where it would presumably be released into the cytoplasm upon infection. K3 is
a membrane-associated ubiquitin ligase, which, along with K5, inhibits antigen presentation on
Major Histocompatibility Complex Class I (MHC Class I) [66] and cell surface expression of receptors
such as DC-SIGN [67]. Despite clear data from overexpression studies showing that K3 can reduce
MHC-I expression at the cell surface [68], previous studies using K3 knockout viruses have led to the
prevailing theory that K3 does not function in this way during lytic reactivation or early infection [46,69].
Importantly, however, the earliest timepoint examined by Brulois et al. in their 2012 study of de novo
infection with a K3 knockout virus was 36 h post-infection, which is well past the window we would
expect to see an effect of K3 as a virion-incorporated factor. Our data that K3 is virion incorporated
establish a new context in which K3 may function very early in the viral life cycle (within hours of
infection) and may provide an explanation for the previous negative data for K3 function in the context
of viral infection.
Finally, we observed three viral interferon regulatory factor (vIRF) proteins as novel
virion-associated proteins in our analysis. K9/vIRF-1 suppresses both type I and type II interferon
responses [70,71]. Similarly, K10.5/vIRF-3 interferes with both type I and type II interferon responses
and additionally can alter CIITA and MHC II expression [72,73]. In 2014, Lee et al. reported that
K10/vIRF4 is a lytic protein capable of suppression of c-IRF4 and c-Myc, thus manipulating the host
gene expression profiles to facilitate viral lytic replication [74]. In 2017, the same group characterized
novel immune evasion strategies of vIRF4 to inhibit the IRF7-mediated IFN-α production [75,76]. It is
not the first time that an immunomodulatory protein has been reported to be prepackaged within
KSHV virion in order to have a quick response against immune recognition; ORF45, as reported by
Zhu et al. [19,77], is not only packaged within the virion but is also known to interact with IRF7.
Our data that three additional vIRFs are encapsulated within the virion necessitate further study into
how these proteins may participate in immune evasion very early in KSHV infection.
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